CRISM Therapeutics Corp 2024 AR2
The report outlines CRISM Therapeutics Corporation's activities and consolidated financial statements for the year ended December 31, 2024. During this transformative year, the company completed a reverse takeover of Amur Minerals Corporation and admitted its shares to trading on the AIM Market. Strategically, the company advanced its lead drug delivery technology, ChemoSeed, towards a Clinical Trial Authorisation application for treating glioblastoma. Financially, the group managed its cash resources to progress clinical trials while reporting a loss for the year of £607,000.
Company: CRISM Therapeutics Corp
Sector: Manufacturing
Country: British Virgin Islands
Year: 2024
Type: AR2
Pages: 54
Back to company
CRISM Therapeutics Corp
Annual Report And Consolidated Financial Statements
The report outlines CRISM Therapeutics Corporation's activities and consolidated financial statements for the year ended December 31, 2024. During this transformative year, the company completed a reverse takeover of Amur Minerals Corporation and admitted its shares to trading on the AIM Market. Strategically, the company advanced its lead drug delivery technology, ChemoSeed, towards a Clinical Trial Authorisation application for treating glioblastoma. Financially, the group managed its cash resources to progress clinical trials while reporting a loss for the year of £607,000.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees